Zynerba Pharmaceuticals Inc

Zynerba Pharmaceuticals — Investor Presentation (April 2018)

39 slides from Zynerba Pharmaceuticals's investor presentation, Apr 10, 2018

  1. Slide 1: Disclaimer

    Disclaimer The statements in this presentation may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements, among other things relate to the future operations,

  2. Slide 2: Zynerba Pharmaceuticals: A Rare/Near-Rare Neuropsychiatric Company

    Two patent protected compounds: ZYN002 (CBD gel) and ZYN001 (THC pro-drug patch) Focused on high unmet medical needs Fragile X syndrome (FXS): ~71K U.S. patients; no approved products Developmental and epileptic encephalopathies (DEE): ~45K U.S. patients Adult refractory focal epilepsy: ~500K U.S. p

  3. Slide 3: Expected 2018 Milestones

    4 Expected 2018 Milestones 1Q 2Q 3Q 4Q ZYN002 Fragile X Syndrome FDA meeting 1Q18 DEE Initiate Phase 2 open label study in 1H18 Adult refractory focal epilepsy Initiate new Phase 2B study in 2H18 Present/publish additional data from STAR 2 extension study in 2018 ZYN001 Tourette Syndrome Complete Ph

  4. Slide 4: ZYN002 Cannabidiol (CBD) Gel

    First and only patent-protected permeation-enhanced pharmaceutically-produced cannabidiol (CBD) gel formulated for transdermal delivery CBD binds to multiple receptors and may mediate a number of pathways, including the endocannabinoid pathway Patented formulation increases the delivery of CBD throu

  5. Slide 5: Fragile X Syndrome: Preparing for 2018 Pivotal Study

    U.S. Orphan Drug Designation for use of CBD as a treatment of Fragile X (Feb. 2016) Positive open label Phase 2 data (Sept. 2017): Achieved primary and numerous secondary endpoints with statistical significance vs. baseline Extremely well tolerated Conducted positive meeting with FDA (Jan. 2018) Exp

  6. Slide 6: Developmental & Epileptic Encephalopathies (DEE): New Phase 2 Program

    Third party clinical data show impact of CBD on seizures and behavioral issues in children BELIEVE 1 Phase 2 study underway Six month multi-dose study in ~50 DEE patients (3 to <18 years) Primary efficacy assessment: change in seizure frequency Results expected in 2019 7 Developmental & Epileptic En

  7. Slide 7: Adult Refractory Focal Epilepsy: Phase 2B Anticipated in 2018

    STAR 2 data suggest clinically meaningful response with longer term use of ZYN002 Consistent improvements in median seizure rate at three, six and nine months of treatment with ZYN002 Updated STAR 2 data accepted as Late Breaking poster at 2018 AAN (April 25, 2018) Learnings from Phase 2 STAR 1 stud

  8. Slide 8: ZYN001 THC Pro-Drug Patch

    9 Patent-protected pharmaceutically-produced D-glyceric acid ester-9-tetrahydrocannabinol (THC) in a transdermal patch ZYN001 is a pro-drug A drug administered in an inactive or less active form, designed to enable more effective delivery, and then converted into a different form through a normal me

  9. Slide 9: Potential for THC in Tourette Syndrome

    10 Potential for THC in Tourette Syndrome (TS) Neurodevelopmental disorder characterized by motor / vocal tics Evident in early childhood ~200K U.S. pts have most severe form Up to 1:100 exhibit milder and less complex symptoms Central cannabinoid receptor system believed to play role in Tourette Sy

  10. Slide 10: Expected 2018 Milestones

    11 Expected 2018 Milestones 1Q 2Q 3Q 4Q ZYN002 Fragile X Syndrome FDA meeting 1Q18 DEE Initiate Phase 2 open label study in 1H18 Adult refractory focal epilepsy Initiate new Phase 2B study in 2H18 Present/publish additional data from STAR 2 extension study in 2018 ZYN001 Tourette Syndrome Complete P

  11. Slide 11: April 2018

    April 2018 Dedicated to the development and commercialization of innovative transdermal pharmaceutically-produced cannabinoid treatments for rare and near-rare neuropsychiatric conditions in patients with high unmet medical needs

  12. Slide 12: ZYN002 CBD Gel Clinical Program: Fragile X Syndrome

    ZYN002 CBD Gel Clinical Program Fragile X Syndrome

  13. Slide 13: Fragile X Syndrome: The Endocannabinoid System is a Critical Pathway

    Rare genetic developmental disability; leading known cause of both inherited intellectual disability and autism spectrum disorder Symptoms linked to deficiencies in the endocannabinoid system ECs form system of neurotransmitters regulating emotional responses, behavioral reactivity to context, socia

  14. Slide 14: Fragile X Syndrome Open Label Phase 2 Trial Design

    Maintenance Dosing initiated at CBD 50 mg Daily; may be titrated up to 250 mg daily Screening Titration Weeks 7 to 12 Day 1 to Week 6 Doses of CBD 50 mg, 100 mg, or 250 mg daily 20 patients enrolled Treatment of Fragile X Syndrome Anxiety and Behavioral Challenges with CBD (FAB-C) Period 1 Period 2

  15. Slide 15: Positive FAB-C Open Label Phase 2 Efficacy Data: ADAMS

    ADAMS total score Improvement vs. baseline (N=20) Changes in Anxiety, Depression and Mood 46% (p<0.0001) ADAMS subscales Improvement vs. baseline (N=20) General Anxiety 54% (p<0.0001) Social Avoidance 53% (p<0.0002) Compulsive Behavior 50% (p=0.0262) Manic/Hyperactive Behavior 35% (p=0.0003) Depress

  16. Slide 16: Positive FAB-C Open Label Phase 2 Efficacy Data: ABC-FXS

    17 ABC-FXS subscale Improvement vs. baseline (N=20) Stereotypy: "Repetitive Movements" 59% (p=0.0006) Social Avoidance: "Seeks Isolation" 55% (p=0.0005) Socially Unresponsive/Lethargic: "Does Not Pay Attention" 53% (p=0.0034) Inappropriate Speech: "Repeats Words or Phrases" 43% (p=0.0018) Irritabili

  17. Slide 17: ADAMS Subscales Week 12 vs. 3rd Party Data

    18 Manic/hyperactive Behavior Depressed Mood Social Avoidance General Anxiety Compulsive Behavior Baseline: 9.4 Baseline: 8.1 8.7 Baseline: 2.8 Baseline: 3.0 3.1 Baseline: 10.2 Baseline: 6.9 7.5 Baseline: 10.0 Baseline: 7.9 8.3 Baseline: 2.8 Baseline: 3.0 3.4 * Ligsay, A., Van Dijck, A., Nguyen, D.

  18. Slide 18: ABC-FXS Subscales Week 12 vs. 3rd Party Data

    19 Irritability Temper Tantrums Hyperactivity Disrupts Group Activities Socially Unresponsive / Lethargic Does Not Pay attention Social Avoidance Seeks Isolation Stereotypy Repetitive Movements Baseline: 18.2 Baseline: 18.9 19.6 Baseline: 14.5 Baseline: 13.9 13.9 Baseline: 8.7 Baseline: 6.6 6.9 Base

  19. Slide 19: Positive FAB-C Open Label Phase 2 Safety Data

    20 Very well tolerated, consistent with previously reported clinical data; no SAEs Two sibling patients discontinued due to worsening of pre-existing eczema No drug-related GI events No THC was detected in the plasma 13 patients continued into open label extension; 12 remain as of 4/2/18 Twelve pati

  20. Slide 20: Fragile X Syndrome Pivotal Study Proposed Trial Design

    Period 1 14 weeks Period 2 12 months Fragile X Syndrome Pivotal Study Proposed Trial Design* ZYN002 Double-blind, placebo-controlled 21 Treatment Open-label extension ZYN002 250 mg daily 500 mg daily (patient weight based) Placebo Sachets to mirror ZYN002 administration *Note: Subject to change due

  21. Slide 21: ZYN002 in Fragile X Syndrome: Next Steps

    22 Expect to begin pivotal trial in pediatric and adolescent patients with FXS mid-year 2018 204 patients from U.S., Australia and New Zealand Key endpoints will assess observable behaviors: ABC-FXS Top line data expected in 2019 Assessing opportunities to present / publish full FAB-C data set as so

  22. Slide 22: ZYN002 CBD Gel Clinical Program: DEE

    ZYN002 CBD Gel Clinical Program Developmental Epileptic Encephalopathies (DEE)

  23. Slide 23: Developmental and Epileptic Encephalopathies

    Heterogeneous group of epilepsy syndromes associated with severe cognitive impairment and behavioral disturbances Syndromes involve: Significant developmental impairment (developmental encephalopathies) Regression of developmental progress (epileptic encephalopathies) Often progressive; highly resis

  24. Slide 24: BELIEVE DEE Open Label Phase 2 Study

    Period 1 Six months Period 2 12 months BELIEVE 1 DEE Open Label Phase 2 Study Results Expected in 2019 ZYN002 25 *Note: Subject to change due to further regulatory, clinical and other considerations. Weight based dosing from 250 to 500 mg daily Screening Titration 2-3 week taper period Extension Tar

  25. Slide 25: ZYN002 CBD Gel Clinical Program: Adult Refractory Focal Epilepsy

    ZYN002 CBD Gel Clinical Program Adult Refractory Focal Epilepsy

  26. Slide 26: Adult Refractory Focal Epilepsy: Phase 2B Anticipated in 2018

    STAR 2 data suggest clinically meaningful response with longer term use of ZYN002 Consistent and improving median seizure rate at three, six and nine months of treatment with ZYN002 Learnings from Phase 2 STAR 1 study and open label STAR 2 extension provide input into Phase 2B trial design Expect to

  27. Slide 27: Epilepsy Phase 2 Clinical Study Trial Design

    Baseline Assess seizure frequency/type Open-Label Extension Synthetic Transdermal CAnnabidiol for the TReatment of Epilepsy ZYN002 CBD 195 mg BID STAR 2 Trial STAR 1 Trial Dose can be adjusted to: BID for 18 months BID for 12 weeks 8 weeks Randomized (1:1:1), double-blind, placebo-controlled - 188 p

  28. Slide 28: STAR 1 Demographics and Baseline Characteristics

    Epilepsy Phase 2 Clinical Study Demographics and Baseline Characteristics ZYN002 STAR 1 patients Placebo 195 mg ZYN002 390 mg ZYN002 Total Pts Randomized 63 63 62 188 Sex 43% male 57% female 51% male 49% female 42% male 58% female 45% male 55% female Pts Analyzed for efficacy 63 62 61 186 Pts comple

  29. Slide 29: STAR 1 and STAR 2 Results

    Epilepsy Phase 2 Clinical Study STAR 1 and STAR 2 Results Company believes study missed primary endpoint due to bimodal distribution of placebo patient responses : >50% reductions in focal seizures in ~¼ of placebo patients 13 of these 15 patients were female Strong separation from placebo seen at >

  30. Slide 30: STAR 1 and STAR 2 Efficacy Data

    Data Presented at 2017 AES STAR 1 and STAR 2 Efficacy Data 31 -8.70 N=63 -18.42 N=62 -14.03 N=61 -13.40 N=59 -32.68 N=55 -30.04 N=55 -26.53 N=24 -65.23 N=21 -48.45 N=18 STAR 1 STAR 2 Week 12 Month 6 Month 3 Median Percent Change in Seizure Rates Placebo ZYN002 195 mg ZYN002 390 mg Placebo (STAR 1) –

  31. Slide 31: Consistent Results at Various Timeframes: Three Months

    32 -18.4 N=62 -14.0 N=61 -13.4 N=59 -32.68 N=55 -30.04 N=55 -26.53 N=24 -65.23 N=21 -48.45 N=18 Median Percent Change in Seizure Rates Dose Regimen in STAR 1 and STAR 2 STAR 2 results based on data collected through mid-August 2017 and in patients who reported seizure frequency data during the respe

  32. Slide 32: Consistent Results at Various Timeframes: Six Months

    33 -18.4 N=62 -14.0 N=61 -13.4 N=59 -32.7 N=55 -30.0 N=55 -26.5 N=24 -65.23 N=21 -48.45 N=18 Median Percent Change in Seizure Rates Dose Regimen in STAR 1 and STAR 2 STAR 2 results based on data collected through mid-August 2017 and in patients who reported seizure frequency data during the respecti

  33. Slide 33: Consistent Results at Various Timeframes: Nine Months

    34 -18.4 N=62 -14.0 N=61 -13.4 N=59 -32.7 N=55 -30.0 N=55 -26.5 N=24 -65.2 N=21 -48.5 N=18 Median Percent Change in Seizure Rates Dose Regimen in STAR 1 and STAR 2 STAR 2 results based on data collected through mid-August 2017 and in patients who reported seizure frequency data during the respective

  34. Slide 34: Proposed Phase 2b Study: Adult Refractory Focal Epilepsy

    ~300 patient double-blind placebo controlled study To be conducted in U.S., Australia and New Zealand Primary endpoint: reduction from baseline in focal seizures 1:1:1 ratio (195 mg: 780 mg: placebo) 35 Learnings from STAR 1 and STAR 2 experience include: Stratified randomization by baseline seizure

  35. Slide 35: Financial Strength

    Cash and cash equivalent position of $62.5 million Includes $3.0 million in net proceeds from shares sold in September and October 2017 under our ATM program Well capitalized, expect cash to fund operations well into 2019 36 Financial Strength As of December 31, 2017

  36. Slide 36: Scientific Advisors

    Elizabeth M. Berry-Kravis, MD, PhD Professor, Department of Pediatrics, Rush Medical College Craig A. Erikson, MD Associate Professor, Department of Psychiatry and Behavioral Neuroscience, Cincinnati Children’s Hospital Randi J. Hagerman, MD Medical Director, UC Davis MIND Institute, Distinguished P

  37. Slide 37: Investor Relations

    38 484.581.7505 [email protected] www.zynerba.com @ZynerbaPharma Zynerba Zynerba Investor Contact Will Roberts, VP, Investor Relations and Corporate Communications 484.581.7489 NASDAQ: ZYNE Analyst Coverage* Ladenburg Thalman: Michael Higgins HC Wainwright: Oren Livnat Piper Jaffray: Cha

  38. Slide 38: April 2018

    April 2018 Dedicated to the development and commercialization of innovative transdermal pharmaceutically-produced cannabinoid treatments for rare and near-rare neuropsychiatric conditions in patients with high unmet medical needs

  39. Slide 39: to the development and

    to the development and ation of innovative transdermal pharm utically-produced cannabinoid treatments for rare and n neuropsychiatric conditions in patients with high unmet m 11 needs April 2018

Zynerba Pharmaceuticals — Investor Presentation (April 2018) on 6ix